Board Leadership Announcement
New Board Treasurer, Patrick Nasr Patrick Nasr has served on the National Cancer Center (“NCC”) Board since 2022 and has recently assumed the role of Treasurer. He received his Bachelor’s…
Read more
New Board Treasurer, Patrick Nasr Patrick Nasr has served on the National Cancer Center (“NCC”) Board since 2022 and has recently assumed the role of Treasurer. He received his Bachelor’s…
Read more
March 3, 2024 08:45 New York Times Many patients are reluctant to undergo colonoscopies or conduct at-home fecal tests. Doctors see potential in another screening method…Read Full Article
All six first-time award winners are women 15 awards representing more than $750K marks another record year of financial support for postdoctoral cancer research Grants benefit researchers at The Dana-Farber…
Read more
According to an article in the New York Times, rectal cancer researchers discovered that elements of cancer treatments may be eliminated to enhance the cancer victim’s quality of life.
Mammograms remain the best screening tool for the early diagnosis of breast cancer, yet dense breasts — that occur in 50% of women who get mammograms — make breast cancer…
Read more
[vc_row][vc_column width=”1/2″][vc_column_text]NEW YORK–(BUSINESS WIRE)–The National Cancer Center is pleased to announce the appointment of David Knorr, M.D., Ph.D., to its Scientific Advisory Board. Dr. Knorr is a medical oncologist currently serving as an…
Read more
[vc_row][vc_column width=”1/2″][vc_column_text]National Cancer Center, in collaboration with the National Association of Health Services Executives New York Regional Chapter invites you to join us for an evening of pilates to honor…
Read more
[vc_row][vc_column width=”2/3″][vc_column_text] We’re excited to share that our organization has earned a 2022 Platinum Seal of Transparency with Candid! Now, you can support our work with trust and confidence by…
Read more
[vc_row][vc_column width=”2/3″][vc_column_text]The National Cancer Center (NCC) recently awarded grants totaling $160,000 to four Dana-Farber researchers pursuing studies into various types of cancer. Carmen Adriaens, MSc, PhD, is studying DNA methylation,…
Read more
A groundbreaking cancer trial at Sloan Kettering of a new drug, dostarlimab, has shown unprecedented results: the cancer disappeared in 100% of the trial participants.
